. 2021 May 10;3(4):100304. doi: 10.1016/j.jhepr.2021.100304

Table 2.

Performance of ctDNA for disease monitoring or prognostication in selected studies.

Study	Target	Patients	Performance	Limitations
ctDNA mutation profiling
Kim et al.,⁹⁷ 2020	2,924 SNVs in 69 genes	107 HCC	MLH1 is associated with poor overall survival	Single MLH1 target
Zhou et al.,⁹⁸ 2020	1,021 gene panel (target not reported)	97 HCC, resected	Associated with shorter disease-free survival	Single liquid biopsy
Alunni-Fabbroni et al.,⁹⁰ 2019	597 gene panel	13 HCC (SORAMIC trial)	cfDNA levels associated with presence of metastases and survival	Small sample size
Oh et al.,⁹⁹ 2019	VEGFA, copy number alteration	151 HCC, 14 healthy controls	Higher cfDNA associated with shorter time to progression (sorafenib), shorter overall survival	Exploratory study
Cai et al.,⁹¹ 2019	CNVs and SNVs, AFP, AFP-L3, DCP	34 HCC, resected	High SNV and CNV correlated with shorter relapse-free survival and overall survival	Small sample size
ctDNA methylation profiling
Xu et al.,⁸² 2017	8 markers	1,098 HCC, 835 healthy controls	Combined prognosis score predicted worse overall survival	Short follow-up

AFP, alpha fetoprotein; cfaDNA, cell-free DNA; CNV, copy number variants; ctDNA, circulating tumour DNA; DCP, des-γ-carboxy-prothrombin; HCC, hepatocellular carcinoma; SNV, single nucleotide variants.